Australia's largest stock trading and investment forum Australia's #1 stock forum

AC8

Click for more information

0.00%

4.0¢ auscann group holdings ltd

Ann: 2019 Annual General Meeting - CEO Presentation, page-16

First 16 Last

Share
Profile

Follow
angelstarlight

170 Posts.

32

30/11/19

12:34

Post #: 41725451
Share

Originally posted by mattstambe: ↑

This is almost exactly the same as what they pushed out a few months ago.

There appears to have been no progress?

All the externally probable markers suggest a different story:

1. There are no registered trials on ANZCTR
2. There are no patents registered
3. There are zero prescribers
4. There are zero patients
5. They is not even a published chemical analysis on any of their "products"
6. There are no TGO93 or TGO100 certificates on any of their prototype "products".

If they really were going to push out a product before the end of 2019 as they are claiming, we would have hoped to have seen a prototype by now or they would have registered some clinical trials by now so they could at least do a Phase 1 study or some pharmacokinetic studies.

I have to say that it does look highly improbably that they will have any products available before the end of the year

Expand

you are funny

Last edited by angelstarlight: 30/11/19

AC8 Price at posting: 20.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

DRO

Droneshield shares move up on $13.5M US govt contract

LMS

Litchfield boosts its copper, base and precious metals footprint in the NT with acquisitions

TMK

TMK Energy kicks off drilling for new pilot wells in Mongolia's vastly underexplored Gobi

OCC

Orthocell wins first international approval for nerve repair product

WAF

West African Res jumps on claim mine safe under Burkina Faso's junta; HotCopper ponders Russia

There are more pages in this discussion • 15 more messages in this thread...

First 16 Last

Add AC8 (ASX) to my watchlist